newsfilter
← Latest News
GlobeNewswire·

Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual J.P. Morgan Healthcare Conference

Continuing Dose Escalation in Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response with Clinical Results Expected in Q1'22 Initial Clinical Results Expected